Nicole K. Yeung

Sydney, NSW, Australia

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications

A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.

A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.

Journal: Cancer research communications
Published: January 06, 2026

High-throughput in vitro drug screening and in vivo studies identify fenretinide as a brain-penetrant DMG therapeutic.

High-throughput in vitro drug screening and in vivo studies identify fenretinide as a brain-penetrant DMG therapeutic.

Journal: Neuro-oncology
Published: February 12, 2025

Characterising the effect of circulating sphingolipids on metastatic prostate cancer cells.

Characterising the effect of circulating sphingolipids on metastatic prostate cancer cells.

Journal: EBioMedicine
Published: January 22, 2025

Plasma Lipidomic Profiling Identifies Elevated Triglycerides as Potential Risk Factor in Chemotherapy-Induced Peripheral Neuropathy.

Plasma Lipidomic Profiling Identifies Elevated Triglycerides as Potential Risk Factor in Chemotherapy-Induced Peripheral Neuropathy.

Journal: JCO precision oncology
Published: May 01, 2024

Overcoming enzalutamide resistance in metastatic prostate cancer by targeting sphingosine kinase.

Overcoming enzalutamide resistance in metastatic prostate cancer by targeting sphingosine kinase.

Journal: EBioMedicine
Published: September 05, 2021

Relationship between Circulating Lipids and Cytokines in Metastatic Castration-Resistant Prostate Cancer.

Relationship between Circulating Lipids and Cytokines in Metastatic Castration-Resistant Prostate Cancer.

Journal: Cancers
Published: August 30, 2021

Aberrations in circulating ceramide levels are associated with poor clinical outcomes across localised and metastatic prostate cancer.

Aberrations in circulating ceramide levels are associated with poor clinical outcomes across localised and metastatic prostate cancer.

Journal: Prostate cancer and prostatic diseases
Published: October 19, 2020

MicroRNAs as potential therapeutics to enhance chemosensitivity in advanced prostate cancer.

MicroRNAs as potential therapeutics to enhance chemosensitivity in advanced prostate cancer.

Journal: Scientific reports
Published: March 02, 2018

Effect of FAK inhibitor VS-6063 (defactinib) on docetaxel efficacy in prostate cancer.

Effect of FAK inhibitor VS-6063 (defactinib) on docetaxel efficacy in prostate cancer.

Journal: The Prostate
Published: September 12, 2017
Showing 1-9 of 9

Last Updated: 09/26/2026